Grant: Doctoral: Vanier Canada Graduate Scholarships
McGill University
$150,000.00
Restoring endogenous muscle stem cell function with eIF4A inhibitors as a treatment for Duchenne muscular dystrophy
EF 2022-23
Résumé
Supervisor: Natasha Chang, McGill. Duchenne muscular dystrophy (DMD) is a lethal neuromuscular disorder affecting 1/3500 live-born males. It is caused by the loss of a protein named dystrophin which stabilizes muscle fibers during contractions. Muscle stem cells are a type of adult stem cell usually kept in a dormant state until activated for differentiation into muscle tissue. These cells also express dystrophin and are responsible for the regeneration of adult muscle. Without dystrophin, muscle stem cells do not differentiate properly and exhibit signs of biological aging, a characteristic known as senescence. DMD therapeutics currently aim towards enhancing quality of life by targeting all muscles in the body. However, no current therapy specifically targets muscle stem cells. Intriguingly, in studies of cachexia, a cancer-related muscle wasting syndrome, treatment with low doses of drugs that inhibit protein synthesis improved muscle differentiation in mice. These drugs eliminated factors that induce cachexia by sequestering them into aggregates within the cytoplasm of the cell. In addition, the formation of these aggregates has been shown to prevent cellular senescence. Given the impaired differentiation and enhanced entry into senescence exhibited by DMD muscle stem cells, we reasoned that treating muscle precursor cells with low doses of these compounds may improve muscle differentiation. Indeed, experiments in our lab have already shown enhanced differentiation following treatment of healthy and DMD muscle precursor cells obtained from mice. The goal of this research project is to continue investigating how these drugs improve muscle differentiation in mouse models of DMD and to uncover their mechanism of action. These findings will enhance our understanding of the pathways that control muscle differentiation in healthy and DMD contexts. Our goal is to provide proof of concept for a new therapeutic approach to enhance muscle stem cell function in DMD.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
474489
Name
Filippelli Romina L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Restoring endogenous muscle stem cell function with eIF4A inhibitors as a treatment for Duchenne muscular dystrophy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Biochemistry; Molecular Biology; Musculoskeletal; Stem Cell Biology
Abstract
Supervisor: Natasha Chang, McGill. Duchenne muscular dystrophy (DMD) is a lethal neuromuscular disorder affecting 1/3500 live-born males. It is caused by the loss of a protein named dystrophin which stabilizes muscle fibers during contractions. Muscle stem cells are a type of adult stem cell usually kept in a dormant state until activated for differentiation into muscle tissue. These cells also express dystrophin and are responsible for the regeneration of adult muscle. Without dystrophin, muscle stem cells do not differentiate properly and exhibit signs of biological aging, a characteristic known as senescence. DMD therapeutics currently aim towards enhancing quality of life by targeting all muscles in the body. However, no current therapy specifically targets muscle stem cells. Intriguingly, in studies of cachexia, a cancer-related muscle wasting syndrome, treatment with low doses of drugs that inhibit protein synthesis improved muscle differentiation in mice. These drugs eliminated factors that induce cachexia by sequestering them into aggregates within the cytoplasm of the cell. In addition, the formation of these aggregates has been shown to prevent cellular senescence. Given the impaired differentiation and enhanced entry into senescence exhibited by DMD muscle stem cells, we reasoned that treating muscle precursor cells with low doses of these compounds may improve muscle differentiation. Indeed, experiments in our lab have already shown enhanced differentiation following treatment of healthy and DMD muscle precursor cells obtained from mice. The goal of this research project is to continue investigating how these drugs improve muscle differentiation in mouse models of DMD and to uncover their mechanism of action. These findings will enhance our understanding of the pathways that control muscle differentiation in healthy and DMD contexts. Our goal is to provide proof of concept for a new therapeutic approach to enhance muscle stem cell function in DMD.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Filippelli, Romina L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~